<link rel="stylesheet" href="https://ajax.googleapis.com/ajax/libs/jqueryui/1.11.4/themes/smoothness/jquery-ui.css">
<link href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.6/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-1q8mTJOASx8j1Au+a5WDVnPi2lkFfwwEAa8hDDdjZlpLegxhjVME1fgjWPGmkzs7" crossorigin="anonymous">


<style> 

.portfolio-view table {
	border-collapse:separate; 
	border-spacing: 0 3px;
	color: #fff;
}
.portfolio-view table tr:first-child td {
	border-top: 3px solid #fff;
}
.targeted-therapies-container .portfolio-table tr {
    background-color: #df7c26;*/
}

.immuno-therapies-container .portfolio-table tr {
    background-color: #07569e;*/
}
.non-oncology-container .portfolio-table tr {
    background-color: #bb2059;*/
}

td {
	width: 250px;
}
table tr:not(:first-child) td:last-child
{
    border-top-right-radius: 20px;*/
    border-bottom-right-radius: 20px;
}

</style>
<script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/2.1.4/jquery.js"></script>
<script src="https://ajax.googleapis.com/ajax/libs/jqueryui/1.11.4/jquery-ui.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.6/js/bootstrap.min.js" integrity="sha384-0mSbJDEHialfmuBBQP6A4Qrprq5OVfW37PRR3j5ELqxss1yVqOtnepnHVP9aJ7xS" crossorigin="anonymous"></script>

<script>
$(function () {

	$("table").mouseenter(function(){
		//alert('yes');
    	$('td').attr("colspan", "0");
	});

});
</script>


<div class="portfolio-view">
   
   <div class="bar-chart-container">
      
	  <div class="chart-legend">
	  </div>

	  <div class="targeted-therapies-container">

		 <table class="table portfolio-table" cellpadding="3" cellspacing="0">
	    
<!-- 		 <thead>
			  <tr>
			    <th colspan="3">Discovery</th>
				<th>Clinical Proof Of Concept</th>
				<th>Pivotal</th>
				<th>Marketed</th>
			  </tr>
			</thead> -->
			<tbody>
	
			</tbody>
		  </table>
	  </div>
	  
	 
	  </div>
	  
	  <div class="footnotes">
	     <!--TODO: HTML Format-->
	     1. Patients with intermediate or high-risk myelofibrosis 2. Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 3. Worldwide rights to capmatinib licensed to Novartis, GBM = Glioblastoma multiforme 4. Phase 3 trial expected to begin in H1 2016 5. Worldwide rights to baricitinib licensed to Lilly, AtD = Atopic dermatitis, SLE = Systemic lupus erythematosus 6. Registration trial expected to begin in H2 2016
	  </div>

	  
   </div>

</div>